Zoledronic acid
- Generic Name
- Zoledronic acid
- Brand Names
- Aclasta, Reclast, Zometa, Zoledronic Acid Accord, Zoledronic acid Actavis, Zoledronic acid medac, Zoledronic acid Teva, Zoledronic Acid Hospira, Zoledronic acid Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C5H10N2O7P2
- CAS Number
- 118072-93-8
- Unique Ingredient Identifier
- 70HZ18PH24
- Background
Zoledronic acid, or CGP 42'446, is a third generation, nitrogen containing bisphosphonate similar to ibandronic acid, minodronic acid, and risedronic acid. Zoledronic acid is used to treat and prevent multiple forms of osteoporosis, hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, and Paget’s disease of bone. Zoledronic acid was first described in the literature in 1994.
Zoledronic acid was granted FDA approval on 20 August 2001.
- Indication
Zoledronic acid is indicated to treat hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, osteoporosis in men and postmenopausal women, glucocorticoid induced osteoporosis, and Paget's disease of bone in men and women. Zoledronic acid is also indicated for the prevention of osteoporosis in post menopausal women and glucocorticoid induced osteoporosis.
- Associated Conditions
- Bone Metastases, Hypercalcemia of Malignancy, Multiple Myeloma (MM), Osteoporosis, Osteoporosis caused by Glucocorticoid Treatment, Paget's Disease of Bone, Paget’s Disease
- Associated Therapies
- Bone Mineral Density
HAIC Combined Withzoledronic Acid for the Prevention of Bone Metastases in Advanced HCC
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Procedure: HAIC
- First Posted Date
- 2023-05-19
- Last Posted Date
- 2023-05-19
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 264
- Registration Number
- NCT05866172
- Locations
- 🇨🇳
Cancer Center Sun Yat-sen University, Guangzhou, Guangdong, China
The Effect of Zoledronate on the Prevention of Pneumonia in Hip Fracture Patients
- First Posted Date
- 2023-02-24
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- The University of Hong Kong
- Target Recruit Count
- 2692
- Registration Number
- NCT05743179
- Locations
- 🇭🇰
Caritas Medical Centre, Sham Shui Po, Hong Kong
🇭🇰Queen Mary Hospital, Hong Kong, Hong Kong
🇭🇰United Christian Hospital, Kwun Tong, Hong Kong
Muscle Impact of Treating Osteoporosis
- Conditions
- SarcopeniaOsteoporosis
- Interventions
- First Posted Date
- 2022-12-27
- Last Posted Date
- 2025-01-07
- Lead Sponsor
- Nami Safai Haeri
- Target Recruit Count
- 20
- Registration Number
- NCT05666310
- Locations
- 🇺🇸
University of Pittsburgh, Pittsburgh, Pennsylvania, United States
Treatment With Zoledronate Subsequent to Denosumab in Osteoporosis 2 (ZOLARMAB2)
- First Posted Date
- 2022-12-16
- Last Posted Date
- 2024-05-02
- Lead Sponsor
- Aarhus University Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT05655013
- Locations
- 🇩🇰
Aarhus University Hospital, Aarhus, Denmark
Denosumab vs Zoledronate After Lumbar Fusion
- Conditions
- Lumbar SpondylolisthesisOsteopenia
- Interventions
- First Posted Date
- 2022-12-06
- Last Posted Date
- 2023-02-21
- Lead Sponsor
- Shenzhen People's Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT05638399
- Locations
- 🇨🇳
ShenzhenPH, Shenzhen, Guangdong, China
Denosumab vs Zoledronate After Vertebroplasty
- Conditions
- Denosumab AllergyZoledronic Acid Allergy
- Interventions
- First Posted Date
- 2022-10-28
- Last Posted Date
- 2023-01-18
- Lead Sponsor
- Shenzhen People's Hospital
- Target Recruit Count
- 75
- Registration Number
- NCT05598606
- Locations
- 🇨🇳
ShenzhenPH, Shenzhen, Guangdong, China
Single or Repeat Zoledronate Versus Alendronate Following Denosumab (EUROpean Denosumab Effects Consolidation Study)
- First Posted Date
- 2022-10-12
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- 424 General Military Hospital
- Target Recruit Count
- 125
- Registration Number
- NCT05575167
- Locations
- 🇫🇷
Univ. Lille, CHU Lille, Lille, France
🇬🇷, KAT General Hospital, Athens, Greece
🇬🇷251 Hellenic Airforce and VA General Hospital, Athens, Greece
Efficacy of Zoledronic Acid to Prevent Bone Loss Following Denosumab Discontinuation
- Conditions
- OsteoporosisOsteoporosis, PostmenopausalOsteopeniaBone Loss
- First Posted Date
- 2022-06-06
- Last Posted Date
- 2024-05-14
- Lead Sponsor
- University of Calgary
- Target Recruit Count
- 20
- Registration Number
- NCT05405894
- Locations
- 🇨🇦
University of Calgary, McCaig Institute for Bone and Joint Health, Calgary, Alberta, Canada
Altering Bone Microarchitecture and Mechanics by Off-label Pharmaceutical Intervention Following an Acute Knee Injury
- Conditions
- Osteo Arthritis KneeAnterior Cruciate Ligament TearAnterior Cruciate Ligament InjuriesAnterior Cruciate Ligament Rupture
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-01-24
- Last Posted Date
- 2023-05-18
- Lead Sponsor
- University of Calgary
- Target Recruit Count
- 56
- Registration Number
- NCT05204836
- Locations
- 🇨🇦
University of Calgary, Calgary, Alberta, Canada
Delayed Versus Immediate Use Of Zoledronic Acid For Postmenopausal Patients With Early Breast Cancer Who Are Using Adjuvant Letrozole
- First Posted Date
- 2021-12-21
- Last Posted Date
- 2021-12-21
- Lead Sponsor
- Assiut University
- Target Recruit Count
- 50
- Registration Number
- NCT05164952
- Locations
- 🇪🇬
Clinical Oncology Department, Assuit University Hospital, Asyūţ, Asyut, Egypt
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.